The phenomenon at the heart of the study is called mistranslation. Ribosomes, the molecular machines that read messenger RNA and assemble proteins, normally interpret each three-letter codon with high fidelity. But when tryptophan runs short, two distinct errors emerge. In one, ribosomes stall at tryptophan codons and slip out of their reading frame, generating entirely different protein sequences from unaltered mRNA, a behaviour the field has dubbed translational sloppiness. In the other, a subtler and arguably stranger process, the tryptophan-transfer RNA is misloaded with phenylalanine, so the ribosome inserts the wrong amino acid while continuing to read the message in frame. The resulting proteins, termed W>F substitutants, carry phenylalanine wherever tryptophan should have been. Previous work had shown that these substitutants accumulate in tumours and correlate with T cell activity, but whether they were merely inevitable accidents of a stressed translation apparatus or actively regulated by the cancer cell’s genome remained an open question.

To answer it, the team built an elegant genetic tool. Their dual-reporter vector places a single tryptophan codon inside the sequence of SIINFEKL, a well-studied peptide that is displayed on the cell surface by the mouse H-2Kb major histocompatibility complex when correctly produced. Downstream, in a different reading frame, sits a turbo-green fluorescent protein that can only be expressed if the ribosome frameshifts at that same tryptophan codon. The system therefore reports both mistranslation modes simultaneously: surface presentation of SIINFEKL signals tryptophan-to-phenylalanine substitution, while green fluorescence signals frameshifting. When the researchers introduced this construct into A549 lung cancer cells and treated them with interferon-gamma, tryptophan-free medium, or both, they observed strong SIINFEKL induction under conditions that depleted tryptophan, and mass spectrometry confirmed that endogenous cellular proteins carried the same W>F substitutions. By comparing peptide intensities, they estimated the median extent of mistranslation at roughly one percent of the relevant proteome, a strikingly high error rate for a process once assumed to be vanishingly rare.

With the reporter validated, the team launched a genome-wide CRISPR-Cas9 knockout screen using the Brunello library, treating the cells with interferon-gamma plus tryptophan depletion and then sorting, by fluorescence-activated cell sorting, the rare cells that retained frameshifting but had lost SIINFEKL presentation. This strategy filtered out genes affecting tryptophan levels or reporter expression and homed in on factors specific to codon reassignment. Alongside expected hits such as WARS1, the tryptophanyl-tRNA synthetase, and antigen-presentation genes including B2M and TAP1, the screen surfaced two unexpected candidates: ADAR1, an adenosine-to-inosine RNA-editing deaminase, and FTSJ1, a 2′-O-methyltransferase that decorates the anticodon loops of several transfer RNAs. Neither had previously been implicated in mistranslation, and their emergence suggested that cancer cells actively invest in the machinery of translational error.

The two enzymes turned out to operate through fundamentally different mechanisms. ADAR1, the team found, is a global enabler of mistranslation. This enzyme resolves double-stranded RNA structures by converting adenosine to inosine, thereby preventing the activation of antiviral sensors such as protein kinase R that would otherwise shut down protein synthesis. When the researchers knocked out ADAR1, global translation dropped, and W>F substitutant production collapsed even though tryptophan remained depleted and IDO1 remained induced. Crucially, re-expressing a wild-type ADAR1 restored substitutant production, whereas a catalytically dead mutant did not, proving that the editing activity itself is required. Proteomics revealed that ADAR1 loss also suppressed histidine-to-glutamine substitutions under histidine starvation, indicating that its influence extends across multiple mistranslation programmes rather than being confined to tryptophan.

Digging deeper, the researchers connected ADAR1 to the ribosome-associated quality control pathway, or RQC, a conserved system that detects stalled and collided ribosomes and resolves them. Knocking out factors acting at or upstream of ribosome splitting, including ZNF598, RACK1 and ABCE1, suppressed W>F substitutants, while disruption of more downstream effectors had little effect. ADAR1-deficient cells showed reduced protein levels of ZNF598, RACK1 and ABCE1, and the authors propose that ADAR1 sustains the expression of this quality-control machinery, which in turn is essential for the aberrant translation events that flourish under nutrient deprivation. Intriguingly, the interferon-inducible p150 isoform of ADAR1, long known to respond to type I interferons, was also induced by interferon-gamma, a type II interferon central to anti-tumour immunity, hinting at a previously underappreciated role for the enzyme in the tumour-immune battleground.

FTSJ1, by contrast, proved to be a specialist. Loss of the enzyme reduced W>F substitutants without touching global translation, frameshifting, or other known mistranslation events such as histidine-to-glutamine and phenylalanine-to-tyrosine substitutions. Transfer RNA sequencing showed that FTSJ1 loss specifically erased methylation marks at positions 32 and 34 of the tryptophan tRNA anticodon loop, modifications that depend on the cofactors THADA and WDR6 respectively. Catalytically inactive FTSJ1 mutants failed to rescue substitutant production, and the effect was reproduced across lung, glioblastoma, breast, melanoma and prostate cancer cell lines, underscoring the generality of the mechanism. The specificity is remarkable: even though FTSJ1 also methylates the phenylalanine tRNA, phenylalanine-to-tyrosine mistranslation was unaffected, pointing to a uniquely tailored role for the tryptophan tRNA modification.

The biochemical explanation emerged from in vitro experiments with recombinant human WARS1, the synthetase that normally charges tryptophan tRNAs with tryptophan. Under tryptophan scarcity, WARS1 can be tricked into loading phenylalanine instead, but this mischarging is inefficient. Using microscale thermophoresis and aminoacylation assays, the team showed that methylated tryptophan tRNA binds far more readily to phenylalanine-bound WARS1 than does unmethylated tRNA, while binding to tryptophan-bound WARS1 is unaffected by the methylation state. In other words, FTSJ1’s chemical marks act as a molecular handshake that only matters when the enzyme is carrying the wrong amino acid. Normal translation proceeds untouched when tryptophan is abundant, but when the immune system strips tryptophan away, the methylated tRNA is perfectly positioned to accept phenylalanine and keep the protein assembly line running.

The consequences ripple outward to cancer immunology. W>F substitutants generate novel peptides, or neoepitopes, presented on HLA molecules, and some of these, such as the broadly shared TMBIM6 W>F neoepitope, can be recognised by T cells and targeted by adoptive cell therapies. The new study shows that FTSJ1 knockout reduces the presentation of W>F neoepitopes in vitro and in xenograft tumours infiltrated by T cells, and correspondingly dampens T cell activation in co-culture assays. This cuts both ways: on one hand, tumours with high FTSJ1 may diversify their immunopeptidome in ways that could invite immune recognition; on the other, the adaptive benefit of sustaining protein synthesis during tryptophan starvation may outweigh that risk, which may explain why both ADAR1 activity and FTSJ1 expression are elevated in tumour tissues compared with adjacent healthy tissue in clinical proteomics datasets. The authors suggest that phenylalanine’s close resemblance to tryptophan makes these substitutions relatively harmless to the cancer cell, allowing translation to continue while limiting the ribotoxic stress that uncharged tRNAs would otherwise provoke.

The study reframes mistranslation not as noise but as a regulated, multi-layered survival programme that tumours deploy under immune pressure. ADAR1 provides the global permissive environment by maintaining ribosome quality control and suppressing antiviral translational shutdown, while FTSJ1 fine-tunes the tryptophan tRNA to exploit phenylalanine as a surrogate substrate. That two RNA-modifying enzymes converge on the same error pathway suggests the process is controlled at multiple stages, and the authors suspect further regulators remain to be found. Given that substitutant-derived neoepitopes are already being explored as immunotherapy targets, understanding the genetics of their production opens a potential new lever: manipulating ADAR1, FTSJ1 or their cofactors could either amplify the neoepitope supply to energise anti-tumour T cells or throttle the translational escape hatch that tumours rely on when the immune system tightens the metabolic screws.

Subject of Research: Genetic regulation of tryptophan-to-phenylalanine mistranslation in cancer cells under immune-mediated tryptophan depletion

Article Title: Global and specific mechanisms stimulate mistranslation in cancer

Article References: Global and specific mechanisms stimulate mistranslation in cancer. (n.d.). https://doi.org/10.1038/s41556-026-02088-3

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02088-3

Keywords: mistranslation, cancer, ADAR1, FTSJ1, tryptophan depletion, W>F substitutants, ribosome quality control, tRNA methylation, WARS1, interferon-gamma, neoepitopes, translational sloppiness

The enzyme at the center of the study, adenosine deaminase acting on RNA 1, or ADAR1, is one of the principal architects of the human transcriptome. It catalyzes the conversion of adenosine to inosine, a process known as A-to-I editing, in double-stranded RNA regions. Because cellular machinery reads inosine as guanosine, this editing can recode messenger RNA transcripts, alter RNA structures, and influence how RNAs are processed, translated or degraded. ADAR1 also plays a well-documented role in innate immunity, where it marks endogenous double-stranded RNA as self and prevents spurious activation of antiviral sensors. In cancer, elevated ADAR1 activity has been linked to tumor progression and immune evasion in several contexts, but its precise contribution to how bladder cancer evades immunotherapy had remained unclear until now.

Using a combination of whole transcriptome sequencing, whole genome sequencing, immunohistochemistry, and patient-derived materials, the team, led by corresponding authors Haiwei Yang, Qiang Lu and Xiao Yang, established that targeting ADAR1 in bladder cancer cells fundamentally reshapes the immune landscape of the tumor microenvironment. When ADAR1 was disabled in experimental models, two critical changes occurred. First, tumors became infiltrated by significantly more CD8-positive T cells, the cytotoxic soldiers of the adaptive immune system that are responsible for directly killing cancer cells. Second, tumor cells increased their expression of PD-L1, the checkpoint ligand through which cancers normally suppress T cell activity. That second change might at first seem counterproductive, but it is precisely what makes the tumors vulnerable to PD-1 blockade: a tumor expressing high levels of PD-L1 but crowded with CD8-positive T cells becomes an ideal target for checkpoint inhibitors, which release the molecular brakes on the waiting immune cells.

To dissect the mechanism, the researchers engineered a mutant form of ADAR1, designated ADAR1-E912A, that is defective in its RNA editing catalytic activity. Comparing cells carrying this editing-defective mutant with cells carrying wild-type ADAR1 allowed them to separate the consequences of the enzyme’s editing function from its other activities. The editing-defective mutant preserved the ability to promote CD8-positive T cell infiltration, and the team traced this effect to the chemokine CCL5, a signaling molecule known to recruit T cells to sites of inflammation and malignancy. Cells expressing the editing-defective mutant produced and secreted more CCL5, creating a chemotactic gradient that drew cytotoxic T lymphocytes into the tumor.

The molecular explanation for the increased CCL5 proved to be a matter of RNA stability. ADAR1 normally edits the messenger RNA encoding CCL5, and these edited transcripts are recognized by endonuclease V, an enzyme that cleaves inosine-containing RNA and thereby destines it for degradation. When ADAR1’s editing function was lost, CCL5 mRNA escaped this editing-dependent degradation pathway, remained stable for longer, and accumulated to higher levels within the cell. The result was a larger pool of CCL5 available for translation and secretion. In effect, ADAR1 acts as a post-transcriptional throttle on one of the most important T cell recruitment signals in the tumor, and switching off that throttle allows the tumor to summon the very immune cells it had been keeping at bay.

The second mechanism the team uncovered concerns PD-L1, the protein through which tumors engage the PD-1 checkpoint on T cells. The researchers found that ADAR1 cooperates with DICER, the cytoplasmic enzyme that processes microRNA precursors into their mature forms, to facilitate the maturation of a specific microRNA, miR-377-3p. Intriguingly, this cooperation did not require ADAR1’s editing catalytic activity, indicating that the protein performs a scaffolding or partner role in the microRNA biogenesis pathway independent of its enzymatic function. Mature miR-377-3p, in turn, represses the expression of PD-L1. In tumors where ADAR1 is abundant, the resulting PD-L1 suppression helps malignant cells keep a low immunological profile even as they hold cytotoxic T cells outside. When ADAR1 is removed, this repression is lifted, PD-L1 rises to the tumor cell surface, and the tumor becomes, paradoxically, an excellent candidate for PD-1 blockade because it now displays the molecular handle that checkpoint drugs are designed to disengage.

Perhaps the most clinically significant element of the study is the identification of an existing drug that can be repurposed as an ADAR1 inhibitor. Fludarabine, a nucleoside analogue long used as a chemotherapeutic agent in hematologic malignancies, was found to suppress ADAR1 on two fronts simultaneously: it inhibited the enzyme’s editing activity and reduced its expression. This dual suppression reproduced the effects seen with genetic targeting of ADAR1. In experimental systems, fludarabine treatment promoted CD8-positive T cell infiltration into tumors, increased PD-L1 expression on tumor cells, and sensitized bladder cancer to PD-1 blockade therapy in both in vitro and in vivo models. The finding suggests that a drug already approved and widely characterized in the clinic could be combined with checkpoint inhibitors to extend their benefits to bladder cancer patients who currently derive little benefit from immunotherapy.

The strength of the study lies partly in the breadth of its experimental evidence. The team worked across multiple platforms, including engineered bladder cancer cell lines with distinct ADAR1 statuses, co-immunoprecipitation and RNA immunoprecipitation assays to map protein and RNA interactions, immunofluorescence combined with fluorescence in situ hybridization to localize molecular events within cells, and quantitative PCR to quantify transcript changes. In vivo, they employed the N-butyl-N-(4-hydroxybutyl) nitrosamine model, a well-established chemical carcinogenesis system for bladder cancer, alongside co-culture experiments with peripheral blood mononuclear cells and experiments using patient-derived organoids that retain features of the original tumors. This triangulation across cell culture, animal models and human-derived material lends considerable weight to the conclusion that ADAR1 targeting genuinely reprograms the tumor microenvironment rather than merely altering isolated molecular readouts.

The implications extend beyond bladder cancer itself. Cold tumors across many cancer types share the fundamental problem of T cell exclusion, and any mechanism that reliably converts cold tumors into hot ones is of broad interest to the oncology community. If ADAR1 functions as a similar gatekeeper in other malignancies, the combination of an ADAR1 inhibitor with PD-1 blockade could represent a generalizable strategy. At the same time, the work highlights the dual and sometimes opposing roles that a single RNA binding protein can play: one activity, the editing of CCL5 mRNA, suppresses immune recruitment, while another, editing-independent cooperation with DICER, suppresses PD-L1 expression. Disentangling these functions will be important as inhibitors are developed and deployed. Fludarabine itself carries a known toxicity profile, and its dosing and safety when combined with checkpoint inhibitors in solid tumors will require careful clinical evaluation. Nevertheless, by identifying a druggable molecular switch that simultaneously pulls immune cells into the tumor and exposes a checkpoint target on the tumor cell surface, the Nanjing team has provided a persuasive mechanistic blueprint for turning one of immunotherapy’s most resistant solid tumors into a far more vulnerable one.

Subject of Research: Targeting the RNA editing enzyme ADAR1 to reprogram the cold tumor microenvironment of bladder cancer and enhance PD-1 blockade immunotherapy

Article Title: Targeting ADAR1 reprograms cold tumors to hot and enhances immunotherapy in bladder cancer

Article References: Bai, K., Zhuang, J., Yu, H., Lv, J., Chen, Y., Jiang, L., Li, K., Yang, H., Lu, Q., & Yang, X. (2026). Targeting ADAR1 reprograms cold tumors to hot and enhances immunotherapy in bladder cancer. Molecular Cancer. https://doi.org/10.1186/s12943-026-02778-4

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02778-4

Keywords: ADAR1, bladder cancer, RNA editing, PD-1 blockade, fludarabine, CD8-positive T cells, PD-L1, CCL5, miR-377-3p, cold tumors, tumor microenvironment, cancer immunotherapy

Viral mimicry was formally described in 2015, when two landmark studies showed that inhibiting DNA methylation in cancer cells could trigger an interferon response without any actual virus being present. The trigger turned out to be endogenous double-stranded RNA derived from endogenous retroviruses and other repeats that had been derepressed by epigenetic drugs. Since then, a large body of work has mapped how this process works at the molecular level. Many transposable elements, including long interspersed nuclear elements such as LINE1 and short interspersed elements such as Alu, retain vestiges of their viral ancestry, including promoter sequences and the capacity to generate RNA species that form double-stranded structures. Pairs of oppositely oriented Alu elements, known as IR-Alus, can fold into intramolecular double-stranded RNA hairpins that are recognized by innate immune sensors such as MDA5, while PKR and ZBP1 provide additional surveillance routes for endogenous double-stranded RNA and Z-form nucleic acids.

The review emphasizes that viral mimicry is not an accidental by-product confined to drug treatment. Cancer-associated alterations in DNA methylation, histone modifications, splicing and RNA processing routinely generate immunogenic nucleic acids in precancerous cells. Global DNA hypomethylation, a common feature of tumour genomes, relaxes repression at repetitive loci; loss of histone marks such as H3K9me3, mediated by enzymes like SETDB1, or disruption of Polycomb repressive complexes derepresses endogenous retroviruses. Splicing defects, which are pervasive across cancer transcriptomes, can create retained introns and aberrant junctions that form double-stranded RNA or Z-RNA structures sensed by MDA5, PKR and ZBP1. Even mitochondrial double-stranded RNA and cytoplasmic RNA–DNA hybrids derived from R-loops can contribute to the endogenous pool of alarm signals. In this sense, the review argues, the pro-tumorigenic regulatory chaos of transformation is inseparable from the collateral production of viral-like nucleic acids.

Viewed through this lens, viral mimicry emerges as a tumour-suppressive mechanism that shapes tumour evolution from its earliest stages. Cells that activate these antiviral programmes can undergo apoptosis, necroptosis, pyroptosis or translational shutdown driven by PKR, or they can attract immune cells through type I interferon signalling that enhances antigen presentation and cytotoxic lymphocyte activity. Recent work describing viral mimicry as a bottleneck in early cancer evolution, including evidence that the pathway acts as a tumour suppressor in inflammatory contexts such as colitis, supports the idea that most cells attempting transformation are eliminated precisely because they cannot simultaneously disrupt their epigenome and silence the repeats that become exposed. Only clones that acquire effective escape mechanisms survive this selective filter, which is why the review frames viral mimicry escape as a prerequisite rather than an option for malignant cells.

The mechanisms cancer cells use to escape are diverse and, the authors argue, reveal a fundamental dependency. On the transcriptional side, tumours often impose compensatory epigenetic repression on repetitive elements, re-engaging DNA methyltransferases, SETDB1, the RB–EZH2 complex or KDM5B to re-silence retroelements. At the RNA level, the editing enzyme ADAR1 converts adenosine to inosine within double-stranded RNA, destabilizing the structures that immune sensors require and acting as a master regulator of viral mimicry escape; high ADAR1 activity is a hallmark of many tumours and is exploited in leukaemia relapse and other contexts. RNA modifications add another layer: N6-methyladenosine deposited by METTL3 and related machinery can reshape double-stranded RNA to prevent sensor recognition and control the fate of endogenous retroviruses. RNA decay enzymes provide a further escape route, with the exonuclease XRN1 degrading retroelement transcripts, while proteins such as DHX9 and the LINE1 ORF1 protein — which acts like a viral innate immune evasion factor — can chaperone or sequester problematic nucleic acids.

Beyond eliminating the trigger molecules themselves, tumours can dampen the downstream signalling that would translate them into an immune response. Sensor pathways can be epigenetically silenced, as has been described for STING and RIG-I–MAVS components in various cancers; interferon signalling itself can be attenuated through regulators such as USP18 and STAT2, or through negative feedback that blunts the antiviral state. Oncogenic drivers also contribute: mutant KRAS in colorectal cancer impairs DDX60-mediated double-stranded RNA accumulation and viral mimicry, converting immunologically hot tumours into cold ones, while p53 loss has been shown to create chronic viral mimicry pressure that selected clones must overcome. Chemotherapy-resistant breast cancers can switch epigenetic states to evade viral mimicry, illustrating that escape is a dynamic, evolving process throughout tumour progression rather than a one-time event.

The review also connects escape mechanisms to biomarkers and therapeutic vulnerabilities. LINE1 ORF1 protein circulating in the blood has been developed as an ultrasensitive multicancer biomarker, and genome-wide repeat landscapes measurable in cell-free DNA reflect the extent of repeat deregulation in individual tumours. Ratios of stemness to interferon signalling have been proposed as biomarkers of progression in myeloproliferative neoplasms. More importantly, every escape mechanism creates a dependency: tumours that rely on ADAR1, XRN1, DHX9, SETDB1 or m6A machinery to survive their own endogenous viral alarm are theoretically vulnerable to drugs that disable those factors. Pharmacological reactivation of viral mimicry — through DNA methyltransferase inhibitors, EZH2 inhibitors, LSD1 inhibitors, spliceosome-targeted therapies, PRMT inhibition or METTL3 blockade — has been shown in preclinical models to restore immunogenicity, and several such approaches are now entering clinical testing.

Combining viral mimicry induction with immunotherapy is a central translational theme. Because viral mimicry activation enhances antitumour immunity and sensitizes cells to immune checkpoint blockade, epigenetic priming with DNMT inhibitors followed by anti-PD1 therapy has shown promise, including in relapsed or refractory NK/T-cell lymphoma, where one of the first trials demonstrating that triggering viral mimicry could augment checkpoint immunotherapy has now been reported. Similar synergy has been observed with EZH2 inhibition in prostate cancer and glioblastoma models, with ZBP1-driven immunogenicity in HER2-directed combinations, and with strategies that restore cGAS–STING and RIG-I–MAVS signalling. Conversely, the review notes that sustained type I interferon signalling can also mediate resistance to some therapies, underscoring that timing, context and combination design matter when manipulating these pathways in patients.

By gathering this evidence into a single conceptual model, the authors propose a reframing of malignant transformation itself: cancer is not simply uncontrolled growth, but uncontrolled growth that has necessarily survived an internal antiviral insurgency of its own making. This unifying model explains why escape mechanisms are so consistently observed across tumour types, why they map onto established dependencies, and why deliberately reactivating viral mimicry represents a rational strategy to expose tumours to their own genome once again. If the framework holds up under experimental and clinical scrutiny, the ancient viral fossils scattered through human DNA may prove to be one of oncology’s most powerful untapped weapons — an alarm that every successful cancer has had to silence, and that medicine may now learn to ring.

Subject of Research: Viral mimicry escape mechanisms in malignant transformation and cancer immunotherapy

Article Title: Viral mimicry escape as a necessary feature of malignant transformation

Article References: Viral mimicry escape as a necessary feature of malignant transformation. (n.d.). https://doi.org/10.1038/s41568-026-00977-1

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00977-1

Keywords: viral mimicry, transposable elements, malignant transformation, epigenetics, interferon signalling, endogenous retroviruses, ADAR1, immune checkpoint blockade, DNA methylation, cancer immunotherapy, innate immunity, double-stranded RNA